This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Osteoporosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Randall S. Stafford, MD, PhD; Rebecca L. Drieling, BA; Adam L. Hersh, MD, PhD

Arch Intern Med. 2004;164:1525-1530.

Background  Research is limited on physicians' prescribing practices for osteoporosis treatment. We investigated patterns of pharmacotherapy from 1988 to 2003 and the impact of new medications on identification and treatment of patients with osteoporosis.

Methods  We tracked trends from 1988 through 2003 in the frequency of osteoporosis visits and patterns of pharmacotherapy associated with these visits using nationally representative data on prescribing patterns by office-based US physicians from the IMS HEALTH National Disease and Therapeutic Index.

Results  The number of physician visits for osteoporosis increased 4-fold between 1994 (1.3 million visits) and 2003 (6.3 million visits), whereas it had remained stable in prior years. This increase coincided with the availability of oral daily bisphosphonates and the selective estrogen receptor modulator raloxifene. The annualized percentage of osteoporosis visits where medications were prescribed increased from 82% in 1988 to 97% by 2003. Prior to 1994, the leading choices for osteoporosis therapy were calcium and estrogens, with lesser roles played by calcitonins and bisphosphonates. Between 1994 and 2003, the percentage of visits where bisphosphonates and raloxifene were prescribed increased from 14% to 73% and from 0% to 12%, respectively, while prescriptions for other medications declined.

Conclusions  New medications for osteoporosis offering improved efficacy and convenient dosing were associated with increased frequency of patient visits and treatment. This finding suggests that new drug therapy contributed to increased disease recognition and treatment.

From the Stanford Prevention Research Center, Stanford University, Palo Alto, Calif. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Undertreatment of Osteoporosis in Men
Arch Intern Med. 2005;165(2):241.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incidence and Mortality of Hip Fractures in the United States
Brauer et al.
JAMA 2009;302:1573-1579.
ABSTRACT | FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration
Patel and Derkits
Journal of Pharmacy Practice 2007;20:341-346.
ABSTRACT  

Americans are not meeting current calcium recommendations
Ma et al.
Am. J. Clin. Nutr. 2007;85:1361-1366.
ABSTRACT | FULL TEXT  

Serum retinyl esters are not elevated in postmenopausal women with and without osteoporosis whose preformed vitamin A intakes are high
Penniston et al.
Am. J. Clin. Nutr. 2006;84:1350-1356.
ABSTRACT | FULL TEXT  

Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.
Nayak et al.
ANN INTERN MED 2006;144:832-841.
ABSTRACT | FULL TEXT  

Undertreatment of Osteoporosis in Men
Arch Intern Med 2005;165:241-241.
FULL TEXT